Clarisse Lorin

Title: Clarisse Lorin: Innovator in Hepatitis B Immunization

Introduction

Clarisse Lorin is a notable inventor based in Rixensart, Belgium. She has made significant contributions to the field of immunology, particularly in the development of immunization regimens for chronic hepatitis B. Her innovative work has the potential to impact public health positively.

Latest Patents

Clarisse Lorin holds 1 patent related to her research. The patent is titled "Hepatitis B immunization regimen and compositions." This invention encompasses immunogenic compositions and combinations that may be utilized in immunization regimens for treating chronic hepatitis B. The compositions include a replication-defective chimpanzee adenoviral (ChAd) vector containing polynucleotides encoding HBs and HBc, as well as a Modified Vaccinia Virus Ankara (MVA) vector with similar polynucleotides. Additionally, the patent describes recombinant HBs, C-terminal truncated recombinant HBc, and an adjuvant containing MPL and QS-21.

Career Highlights

Clarisse Lorin is associated with GlaxoSmithKline Biologicals SA, where she continues her research and development efforts. Her work in the pharmaceutical industry has been instrumental in advancing vaccine technology and improving immunization strategies.

Collaborations

Throughout her career, Clarisse has collaborated with esteemed colleagues, including Virginia Ammendola and Babak Bayat. These partnerships have fostered innovation and contributed to the success of her projects.

Conclusion

Clarisse Lorin's contributions to hepatitis B immunization represent a significant advancement in medical science. Her innovative approaches and collaborations highlight her commitment to improving public health through effective immunization strategies.